Fulgent Genetics

In News

Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial - Stock Titan

Stock Titan - May 21, 2026

Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab - TradingView

TradingView - May 21, 2026

FinancialContent - Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - FinancialContent

FinancialContent - May 21, 2026

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire

GlobeNewswire - May 20, 2026

Foundation Medicine links with Fulgent Genetics to offer new gene test - Fierce Biotech

Fierce Biotech - May 05, 2026

Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com Canada

Investing.com Canada - May 21, 2026

Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused Expansion - What's Changed - Yahoo Finance

Yahoo Finance - Mar 02, 2026

Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair - Traders Union

Traders Union - May 19, 2026

How many employees work at Fulgent Therapeutics? - Revelio Labs

Revelio Labs - May 06, 2026

Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN

MSN - May 15, 2026

Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha

Seeking Alpha - Mar 12, 2026

Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant - Stock Titan

Stock Titan - May 18, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment